Wedbush Keeps Their Hold Rating on Intellia Therapeutics (NTLA)
I'm PortAI, I can summarize articles.
Wedbush analyst maintained a Hold rating on Intellia Therapeutics today and set a price target of $7.00.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. In addition to Wedbush, Intellia Therapeutics also received a Hold from JonesTrading’s Debanjana Chatterjee in a report issued today. However, yesterday, Truist Financial reiterated a Buy rating on Intellia Therapeutics (NASDAQ: NTLA).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments